25,729 articles
Behr syndrome
Behr syndrome (Behr complicated familial optic atrophy, OMIM 210000) is a genetically heterogeneous childhood-onset optic atrophy with ataxia, spasticity, neuropathy, and cognitive impairment; genes include C12orf65, OPA1, OPA3, C19orf12; treatment is supportive.
Beijing Shijitan Hospital
Beijing Shijitan Hospital (北京世纪坛医院), affiliated to Capital Medical University, is a Grade III-A general hospital in Haidian, Beijing. Founded 1915 as a railway hospital, renamed 2005; 1,100 beds; developed the SJT VTE risk model.
Beinaglutide
Beinaglutide (贝那鲁肽, Yishengtai) is a short-acting GLP-1 receptor agonist, recombinant human GLP-1(7-36) with 100% human sequence, developed by Shanghai Benemae and approved in China in December 2016 for type 2 diabetes and weight management.
BEIP trial
The BEIP trial, or Bucharest Early Intervention Project, is the only randomized trial comparing foster care with institutional care for abandoned children, begun in Bucharest, Romania, around 2000.
Bekanamycin
Bekanamycin (kanamycin B, kanendomycin) is an aminoglycoside antibiotic from Streptomyces kanamyceticus, marketed in Japan in 1969, ATC J01GB13, WHO AWaRe Watch group, roughly twice as active in vitro as kanamycin A.
Béla Merkely
Béla Merkely (Merkely Béla Péter, born 1966) is a Hungarian interventional cardiologist, rector of Semmelweis University since 2018 and director of its Városmajor Heart and Vascular Center, a Széchenyi Prize winner and ESC Vice-President 2016–2018.
Belantamab mafodotin
Belantamab mafodotin (belamaf, Blenrep, GSK2857916) is a first-in-class BCMA-targeting antibody-drug conjugate with MMAF payload for multiple myeloma; approved 2020, withdrawn 2023, reapproved 2025; hallmark toxicity is keratopathy.
Belaswitch study
Belaswitch (NCT05316038), also called the belatacept conversion study, is a prospective single-center cohort study at Grenoble Alpes University Hospital tracking metabolic and infectious complications in kidney transplant recipients switched from tacrolimus to belatacept, each patient as their own control.
Belatacept
Belatacept (Nulojix) is an intravenous T-cell costimulation blocker approved in 2011 to prevent kidney transplant rejection, offering better graft function and metabolic outcomes than calcineurin inhibitors but higher acute rejection risk than tacrolimus.
Belching
Belching, also called eructation or burping, is the audible escape of air from the esophagus or stomach into the pharynx, usually normal but a disorder when excessive.
Belimumab
Belimumab (Benlysta, formerly LymphoStat-B) is a fully human IgG1λ monoclonal antibody neutralizing BLyS/BAFF; FDA-approved March 2011 as the first SLE-specific drug in over 50 years, later for lupus nephritis and pediatric SLE.
Belinostat
Belinostat (Beleodaq, PXD101) is a hydroxamate pan-HDAC inhibitor approved July 2014 under FDA accelerated approval for relapsed/refractory peripheral T-cell lymphoma, based on the single-arm BELIEF trial (ORR 25.8%).
Bell's palsy
Bell's palsy, or idiopathic facial nerve palsy, is sudden one-sided facial weakness, the most common cause of facial paralysis; steroids within 72 hours help, and most patients recover within 3 to 6 months.
Belle Gibson
Belle Gibson (Annabelle Natalie Gibson), Australian wellness influencer behind The Whole Pantry app and book, faked a terminal brain cancer cure through diet, admitted the lie in 2015, and was fined A$410,000 by the Federal Court in 2017; the fines remain unpaid.
Bellevue Hospital
Bellevue Hospital (NYC Health + Hospitals/Bellevue), founded 1736 as a six-bed Almshouse infirmary, is America's oldest public hospital, a Manhattan Level I trauma center affiliated with NYU, serving about 520,000 outpatients yearly.
BELONG-EGPA study
BELONG-EGPA (NCT07815886) is a European EGPA Study Group multicenter retro-prospective observational study of benralizumab 30 mg every 4 weeks in adults with EGPA, tracking 24-month real-world effectiveness, relapse, and safety.
Beloranib
Beloranib (CKD-732, ZGN-440, ZGN-433): fumagillin-analogue MetAP2 inhibitor obesity drug by Zafgen and Chong Kun Dang; effective in trials but halted in 2015 after fatal pulmonary embolisms.
Belotecan
Belotecan (CKD602, Camtobell), a semi-synthetic camptothecin analogue topoisomerase I inhibitor developed by Chong Keun Dang; approved for clinical use and studied in small-cell lung and ovarian cancer versus topotecan.
Below-knee amputation
Below-knee amputation, also called transtibial amputation, is surgery that removes the foot, ankle, and lower leg bones while preserving the knee, typically for critical limb ischemia or diabetic foot infection.
Belrestotug
Belrestotug (EOS-448, GSK4428859A) is a human IgG1 anti-TIGIT monoclonal antibody from iTeos Therapeutics and GSK for solid tumors; its Phase 3 GALAXIES Lung-301 NSCLC programme was halted in May 2025 after Phase 2 interim analyses missed efficacy criteria.
Belumosudil
Belumosudil (Rezurock) is an oral selective ROCK2 inhibitor approved in 2021 for chronic graft-versus-host disease after at least two failed systemic therapy lines, combining immunomodulatory and antifibrotic actions.
Belzupacap sarotalocan
Belzupacap sarotalocan (bel-sar, AU-011) is Aura Biosciences' investigational virus-like drug conjugate of HPV-derived VLPs conjugated to IR700 dye, activated by 689 nm near-infrared light to kill HSPG-expressing tumor cells; in phase 3 for choroidal melanoma.
Belzutifan
Belzutifan (Welireg, MK-6482) is Merck's first-in-class oral HIF-2α inhibitor approved for VHL disease-associated tumors (2021), advanced clear cell renal cell carcinoma (2023), pheochromocytoma/paraganglioma (2025), and RCC combinations (2026).
Bemarituzumab
Bemarituzumab (FPA144, AMG 552) is a first-in-class afucosylated humanized IgG1 antibody against FGFR2b, developed for FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma; tested in the FIGHT phase 2 and FORTITUDE-101 phase 3 trials.
Bemiparin sodium
Bemiparin sodium (Hibor, Ivor, Zibor, Badyket) is a second-generation low-molecular-weight heparin from ROVI, mean MW 3,600 Da, anti-Xa/IIa ratio 8, once-daily subcutaneous prophylaxis and treatment of venous thromboembolism and hemodialysis anticoagulation.
Bemnifosbuvir
Bemnifosbuvir (AT-527, RO7496998) is an oral guanosine nucleotide analogue prodrug of AT-9010, a viral RNA polymerase inhibitor developed by Atea Pharmaceuticals for hepatitis C and, unsuccessfully, COVID-19; now Phase 3 with ruzasvir for HCV.
Bempedoic acid
Bempedoic acid (Nexletol, Nilemdo; with ezetimibe as Nexlizet, Nustendi) is an oral ATP citrate lyase inhibitor lowering LDL-C; CLEAR Outcomes showed 13% fewer major cardiovascular events in statin-intolerant patients.
Ben D. Barker
Ben D. Barker, also known as Bennie Dale Barker, was an American dental education scholar and dean of the UNC-Chapel Hill School of Dentistry from 1981 to 1989.
Ben Wa balls
Ben Wa balls, also called Kegel balls, orgasm balls, or geisha balls, are small weighted balls inserted vaginally for pelvic floor exercise or pleasure; evidence is limited and risks include pain, overactive muscles, and infection.
Benadryl
Benadryl, the brand name for diphenhydramine, is a first-generation antihistamine synthesized in 1943 by George Rieveschl and launched in 1946 by Parke, Davis as the first popular oral antihistamine, used for allergies, sleep, and motion sickness.